Press releases Featured Oct 11, 2024 NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Oct 11, 2024 Oct 11, 2024 Jul 11, 2024 NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Jul 11, 2024 Jul 11, 2024 Jun 18, 2024 NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Jun 18, 2024 Jun 18, 2024 Jun 11, 2024 NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Jun 11, 2024 Jun 11, 2024 Mar 22, 2024 NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Mar 22, 2024 Mar 22, 2024 Mar 21, 2024 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Mar 21, 2024 Mar 21, 2024 Mar 1, 2024 NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences Mar 1, 2024 Mar 1, 2024 Jan 22, 2024 NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services Jan 22, 2024 Jan 22, 2024 Nov 15, 2023 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Nov 15, 2023 Nov 15, 2023 Oct 3, 2023 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Oct 3, 2023 Oct 3, 2023 Sep 26, 2023 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Sep 26, 2023 Sep 26, 2023 Sep 8, 2023 NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association Sep 8, 2023 Sep 8, 2023 Jun 20, 2023 NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Jun 20, 2023 Jun 20, 2023 Jun 9, 2023 NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting Jun 9, 2023 Jun 9, 2023 Jun 1, 2023 NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy Jun 1, 2023 Jun 1, 2023 May 23, 2023 NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 May 23, 2023 May 23, 2023 Jan 3, 2023 Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Jan 3, 2023 Jan 3, 2023 Dec 14, 2022 NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Dec 14, 2022 Dec 14, 2022 Oct 11, 2022 NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Oct 11, 2022 Oct 11, 2022 Sep 27, 2022 FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis Sep 27, 2022 Sep 27, 2022 May 10, 2022 NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer May 10, 2022 May 10, 2022 May 3, 2022 NMD Pharma expands its US presence May 3, 2022 May 3, 2022 Feb 15, 2022 NMD Pharma Raises €35 Million in a new Financing Feb 15, 2022 Feb 15, 2022 Jul 8, 2021 NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease Jul 8, 2021 Jul 8, 2021 Jun 30, 2021 NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Jun 30, 2021 Jun 30, 2021 Jun 1, 2021 NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults Jun 1, 2021 Jun 1, 2021 Nov 30, 2020 NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth Nov 30, 2020 Nov 30, 2020 Nov 30, 2020 NMD Pharma Receives Grant from The Innovation Fund Denmark Nov 30, 2020 Nov 30, 2020 Oct 6, 2020 NMD Pharma Initiates Combined Phase I/II Clinical trial Oct 6, 2020 Oct 6, 2020 Jul 15, 2020 NMD Pharma begins first clinical trial Jul 15, 2020 Jul 15, 2020